Alexion Pharmaceuticals Inc. has reached a tentative settlement with U.S. authorities under which the company would pay less than $25 million to resolve claims it violated an antibribery law.
The Boston-based biopharmaceutical company in its annual report Wednesday said it has reached an agreement in principle with the U.S. Securities and Exchange Commission to resolve the Foreign Corrupt Practices Act investigation.
The probe, focusing on Alexion’s grant-making activities and FCPA compliance in a number of countries, has been under way since about May 2015, when the company received a subpoena from the SEC, Alexion said.
The full original article can be found at wsj.com
(Photo: Kris Tripplaar/Sipa USA/Newscom)